File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial
  • Basic View
  • Metadata View
  • XML View
TitleTreatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial
 
AuthorsTan, VPY1
Wong, WM1
Cheung, TK1
Lai, KC1
Hung, IFN1
Chan, P1
Pang, R1
Wong, BCY1
 
KeywordsClinical trial
GERD
Proton pump inhibitor
 
Issue Date2011
 
PublisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm
 
CitationJournal Of Gastroenterology, 2011, v. 46 n. 7, p. 906-912 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00535-011-0402-1
 
AbstractBackground: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. Methods: Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. Results: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. Conclusions: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease. © 2011 Springer.
 
ISSN0944-1174
2013 Impact Factor: 4.020
2013 SCImago Journal Rankings: 1.724
 
DOIhttp://dx.doi.org/10.1007/s00535-011-0402-1
 
ISI Accession Number IDWOS:000292607300006
Funding AgencyGrant Number
University of Hong Kong
Funding Information:

We thank AstraZeneca Hong Kong for the supply of the study medicine and the identical placebo tablets. The study was supported by the Simon KY Lee Endowment Professorship, and the outstanding researcher award 2005-2006 of the University of Hong Kong.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTan, VPY
 
dc.contributor.authorWong, WM
 
dc.contributor.authorCheung, TK
 
dc.contributor.authorLai, KC
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorChan, P
 
dc.contributor.authorPang, R
 
dc.contributor.authorWong, BCY
 
dc.date.accessioned2011-09-23T05:50:42Z
 
dc.date.available2011-09-23T05:50:42Z
 
dc.date.issued2011
 
dc.description.abstractBackground: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. Methods: Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. Results: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. Conclusions: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease. © 2011 Springer.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationJournal Of Gastroenterology, 2011, v. 46 n. 7, p. 906-912 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00535-011-0402-1
 
dc.identifier.citeulike9264538
 
dc.identifier.doihttp://dx.doi.org/10.1007/s00535-011-0402-1
 
dc.identifier.epage912
 
dc.identifier.hkuros196569
 
dc.identifier.hkuros203200
 
dc.identifier.isiWOS:000292607300006
Funding AgencyGrant Number
University of Hong Kong
Funding Information:

We thank AstraZeneca Hong Kong for the supply of the study medicine and the identical placebo tablets. The study was supported by the Simon KY Lee Endowment Professorship, and the outstanding researcher award 2005-2006 of the University of Hong Kong.

 
dc.identifier.issn0944-1174
2013 Impact Factor: 4.020
2013 SCImago Journal Rankings: 1.724
 
dc.identifier.issue7
 
dc.identifier.openurl
 
dc.identifier.pmid21538030
 
dc.identifier.scopuseid_2-s2.0-79960319148
 
dc.identifier.spage906
 
dc.identifier.urihttp://hdl.handle.net/10722/139500
 
dc.identifier.volume46
 
dc.languageeng
 
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm
 
dc.publisher.placeJapan
 
dc.relation.ispartofJournal of Gastroenterology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.subject.meshAnxiety
 
dc.subject.meshDouble-Blind Method
 
dc.subject.meshGastroesophageal Reflux - drug therapy - psychology
 
dc.subject.meshOmeprazole - therapeutic use
 
dc.subject.meshProton Pump Inhibitors - therapeutic use
 
dc.subjectClinical trial
 
dc.subjectGERD
 
dc.subjectProton pump inhibitor
 
dc.titleTreatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tan, VPY</contributor.author>
<contributor.author>Wong, WM</contributor.author>
<contributor.author>Cheung, TK</contributor.author>
<contributor.author>Lai, KC</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Chan, P</contributor.author>
<contributor.author>Pang, R</contributor.author>
<contributor.author>Wong, BCY</contributor.author>
<date.accessioned>2011-09-23T05:50:42Z</date.accessioned>
<date.available>2011-09-23T05:50:42Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Journal Of Gastroenterology, 2011, v. 46 n. 7, p. 906-912</identifier.citation>
<identifier.issn>0944-1174</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/139500</identifier.uri>
<description.abstract>Background: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. Methods: Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. Results: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. Conclusions: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease. &#169; 2011 Springer.</description.abstract>
<language>eng</language>
<publisher>Springer Japan. The Journal&apos;s web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm</publisher>
<relation.ispartof>Journal of Gastroenterology</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<subject>Clinical trial</subject>
<subject>GERD</subject>
<subject>Proton pump inhibitor</subject>
<subject.mesh>Anxiety</subject.mesh>
<subject.mesh>Double-Blind Method</subject.mesh>
<subject.mesh>Gastroesophageal Reflux - drug therapy - psychology</subject.mesh>
<subject.mesh>Omeprazole - therapeutic use</subject.mesh>
<subject.mesh>Proton Pump Inhibitors - therapeutic use</subject.mesh>
<title>Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0944-1174&amp;volume=46&amp;issue=7&amp;spage=906&amp;epage=912&amp;date=2011&amp;atitle=Treatment+of+non-erosive+reflux+disease+with+a+proton+pump+inhibitor+in+Chinese+patients:+a+randomized+controlled+trial</identifier.openurl>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s00535-011-0402-1</identifier.doi>
<identifier.pmid>21538030</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79960319148</identifier.scopus>
<identifier.hkuros>196569</identifier.hkuros>
<identifier.hkuros>203200</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79960319148&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>46</identifier.volume>
<identifier.issue>7</identifier.issue>
<identifier.spage>906</identifier.spage>
<identifier.epage>912</identifier.epage>
<identifier.isi>WOS:000292607300006</identifier.isi>
<publisher.place>Japan</publisher.place>
<identifier.citeulike>9264538</identifier.citeulike>
</item>
Author Affiliations
  1. The University of Hong Kong